Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696778 | 0.90 | USP30 (0.56) | STSUSP30ACHETACR1KEAP1 | |
| SCHEMBL4875893 | 0.90 | JAK1 (0.54) | STSNAMPTUSP30ACHETACR1 | |
| SCHEMBL10449417 | 0.90 | JAK1 (0.54) | STSNAMPTUSP30ACHETACR1 | |
| SCHEMBL10320157 | 0.90 | JAK1 (0.54) | STSNAMPTUSP30ACHETACR1 | |
| SCHEMBL29043109 | 0.90 | USP30 (0.56) | STSUSP30ACHETACR1KEAP1 | |
| SCHEMBL22435955 | 0.90 | JAK1 (0.54) | STSNAMPTUSP30ACHETACR1 | |
| SCHEMBL696779 | 0.90 | USP30 (0.56) | STSUSP30ACHETACR1KEAP1 | |
| SCHEMBL29577032 | 0.89 | JAK2 (0.46) | STSNAMPTUSP30ACHETACR1 | |
| SCHEMBL13641448 | 0.88 | KMT2A (0.53) | NAMPTACHEGPR119LMNA | |
| SCHEMBL22222650 | 0.88 | USP30 (0.62) | STSUSP30ACHEKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022149057-A1 | CDK INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2022-07-14 | — | — | WO | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9221792-B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | AGIOS PHARMACEUTICALS, INC (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2651898-B1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL)PHENYL)-(HETERO-)ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2651898-B1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL)PHENYL)-(HETERO-)ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2651898-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | Agios Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK3, PDK2 | STS 1844/4885NAMPT 490/4885USP30 3651/4885 |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | PDK2, PDK3, PDK4 | STS 2032/4885NAMPT 1888/4885USP30 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.